ESR1 and Alzheimer disease: Surprisingly, we discovered that two recently identified therapeutic target families of neurodegenerative disease, the histone deacetylase (HDAC) family and estrogen receptor (ER) family, might have already been involved in the therapeutic pathways of these marketed AD drugs.